https://doi.org/10.55788/0da352e1
“The Swiss PH Registry is a collaboration between 13 Swiss hospitals that has been established in 1998, and includes patients with newly diagnosed pulmonary hypertension from 2000 onwards,” stated Dr Anna Titz (University Hospital Zürich, Switzerland) [1]. Registry data from 2001–2019 served as a basis for a retrospective analysis that assessed epidemiology and long-term outcomes of patients with CpcPH [1,2]. CpcPH was defined by a mean mPAP over 20 mmHg and a pulmonary vascular resistance (PVR) above 2 Wood units. The study comprised a Kaplan-Meier survival analysis and a Cox regression analysis that included baseline characteristics, risk assessment strata, 6-minute-walking test scores, and BNP/NT-proBNP levels. The study cohort consisted of 231 patients, among them 137 women. Further assessment of demographics observed a mean age of 65, a mean mPAP of 48 mmHg, and a mean PVR of 7.2 Wood units. “Surprisingly, our data shows that 47% of our cohort received PH-targeted medication,” Dr Titz emphasised, while mentioning the conflicting evidence that currently exists regarding these medication in patients with PH based on left heart disease.
The results demonstrated a statistically significant higher survival probability for women compared with men (P=0.011). One factor influencing survival was mPAP, as having an mPAP over 46 mmHg was linked to higher mortality (P=0.035). “We also stratified our patients according to the 4-strata risk assessment tool, by using the non-invasively assessed parameters: functional class, 6-minute walking test, and NT-proBNP,” Dr Titz informed. These results showed that high-risk patients in the 4-strata risk assessment have a lower survival probability than those with low/intermediate risk. These findings were also corroborated by the results of the Cox regression analysis, with significant hazard ratios of 0.58 for being female, 1.58 for mPAP >46 mmHg, and 2.44 for high-risk patients (see Figure). However, a significant influence on survival of age or pulmonary vascular resistance could not be established.
“In this patient cohort with combined post- and pre-capillary pulmonary hypertension, women and patients with a lower mPAP revealed a longer survival,” Dr Titz summarised.
Figure: Cox regression analysis: Women have a statistically significant higher survival probability [1]
- Titz A. Long-term outcome of patients with combined post- and precapillary pulmonary hypertension. Abstract 747, ERS 2023 Congress, 9–13 September, Milan, Italy.
- Titz A, et al. Eur Heart J Open. 2023 Jul 3;3(4):oead069.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Women at higher risk of functional respiratory complaints following a COVID-19 infection Next Article
Chronic thromboembolic pulmonary hypertension: surgery entails encouraging long-term results »
« Women at higher risk of functional respiratory complaints following a COVID-19 infection Next Article
Chronic thromboembolic pulmonary hypertension: surgery entails encouraging long-term results »
Table of Contents: ERS 2023
Featured articles
Letter from the Editor
Best of the Posters
sRAGE: A novel potential biomarker to assess the risk of acute respiratory events
Most severe asthma patients are candidates for biologic therapy on a global scale
Aspergillus infections: resistance to azole treatment increased in the presence of diesel particles
Asthma in 2023
Tapering from high-dose inhaled corticosteroids possible in most asthma patients treated with benralizumab
Tezepelumab therapy: hints toward a disease-modifying effect?
Digital inhaler programme improves asthma control also in the long term, but not long-term adherence
Respiratory health in children
Large infant study demonstrates the importance of a mature microbiome
Healthy maternal lifestyle during pregnancy reduces wheezing and rhinitis in infants
Mechanism of autophagy in a newborn responsible for deleterious effect of air pollutants
COPD: New Developments
Gabapentinoids increase risk of exacerbations in COPD
Future treatment of fatigue in COPD: 4 possible targets identified
Pulmonary Consequences of Long COVID
Women at higher risk of functional respiratory complaints following a COVID-19 infection
Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID
Pulmonary Arterial Hypertension (PAH): Novel Developments
Encouraging long-term outcomes observed in the treatment of PAH with sotatercept
Chronic thromboembolic pulmonary hypertension: surgery entails encouraging long-term results
Women with pulmonary hypertension have better survival chances than men
Rare Diseases in 2023
Primary ciliary dyskinesia: Idrevloride shows promising results in phase 2 trial
Promising new agent as treatment for pulmonary fibrosis
Novel immunomodulator offers hope to reduce steroid dependency in sarcoidosis
Other Research of Interest
Tacrolimus versus cyclosporin: Less lung graft dysfunction
CPAP effective in reducing cardiovascular mortality in a practice study
Gefapixant curbs chronic cough independent of its duration
Related Articles
June 12, 2023
Practice-changing results for ensifentrine in COPD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy